Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Navacaprant · NMRA-335140, BTRX-335140

Small molecule · developed by Neumora Therapeutics

Phase 3 Most advanced trial (none active)
NMRA Developer
2 Registered trials

What is Navacaprant?

Navacaprant (NMRA-335140) is an orally administered agent studied at 80 mg once daily over a 52-week treatment period in major depressive disorder and in major depressive episodes associated with bipolar II disorder.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
NMRA-335140, BTRX-335140, CYM-53093, BTRX-140
Drug type
Small molecule
Therapy area
Psychiatry
Developer
Neumora Therapeutics, Inc. (NMRA)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
XK5ILZ28KI

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06029439 Phase 3 Major Depressive Disorder Terminated NMRA
NCT06429722 Phase 2 Major Depressive Episode Associated With Bipolar II Disorder Completed NMRA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Major Depressive DisorderMajor Depressive Episode Associated With Bipolar II Disorder

More from Neumora Therapeutics

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the NMRA page.

Follow NMRA, the company behind Navacaprant

See NMRA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NMRA catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.